We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oncternal Therapeutics: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Oncternal Therapeutics, Inc. (ONCT) on Thursday reported a loss of $9.2 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of $3.11.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $3.09 per share.
The biopharmaceutical company posted revenue of $297,000 in the period, which topped Street forecasts. Three analysts surveyed by Zacks expected $170,000.
For the year, the company reported a loss of $39.5 million, or $13.43 per share. Revenue was reported as $785,000.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ONCT at https://www.zacks.com/ap/ONCT
Copyright 2024, Associated Press, The